BMP-2 delivered from a self-cross-linkable CaP/hydrogel construct promotes bone regeneration in a critical-size segmental defect model of non-union in dogs

Summary

Objectives: To determine whether the addition of recombinant human bone morphogenetic protein (rhBMP-2) to a self-crosslinkable cellulosic hydrogel/biphasic calcium phosphate (BCP) granules construct promotes bone healing in critical-size ulnar defects in dogs.

Methods: A standardized 2 cm long ulnar ostectomy was performed bilaterally in five dogs to compare bone healing with hydrogel/BCP constructs associated with or without rhBMP-2. Cancellous-bone autografts were used as positive controls in unilateral ulnar defects in five additional dogs. Radiographically, bone healing was evaluated at four, eight, 12, 16 and 20 weeks postoperatively. Histological qualitative analysis with microCT imaging and light and scanning electron microscopy were performed 20 weeks after implantation.

Results: All rhBMP-2-loaded constructs induced the formation of well-differentiated mineralized lamellar bone surrounding the BCP granules and bridging bone/implant interfaces as early as eight weeks after surgery. Bone regeneration appeared to develop earlier with the rhBMP-2 constructs than with the cancellous-bone autografts while similar results were obtained at 20 weeks. Constructs without any rhBMP-2 showed osteoconductive properties limited to the bone junctions and a lack of osteoinduction without bone ingrowth within the implantation site. In one dog, the leakage of the hydrogel loaded with rhBMP-2 induced an extensive heterotopic bone formation.

Clinical significance: The addition of rhBMP-2 to a self-crosslinkable hydrogel/BCP construct could promote bone regeneration in a critical-size-defect model with similar performance to autologous bone grafts.

Keywords

Recombinant human bone morphogenetic protein - BMP-2 - calcium phosphate hydrogel - bone union - critical sized defect - dog

• References

• 1 Block MS, Kent JN. Sinus augmentation for dental implants: the use of autogenous bone. J Oral Maxillofac Surg 1997; 55: 1281-1286.
• 2 Huble MJ. Bone grafts. Surg Technol Int 2002; 10: 261-265.
• 3 Daculsi G, Passuti N, Martin S. et al. Macroporous calcium phosphate ceramic for long bone surgery in humans and dogs. Clinical and histological study. J Biomed Mater Res 1990; 24: 379-396.
• 4 Bauer TW, Smith ST. Bioactive materials in orthopedics surgery: overview and regulatory considerations. Clin Orthop Rev 2002; 395: 11-22.
• 5 Gauthier O, Müller R, von Stechow D. et al. In vivo bone regeneration with injectable calcium phosphate biomaterial: a three-dimensional micro-computed tomographic, biomechanical and SEM study. Biomaterials 2005; 26: 5444-5453.
• 6 Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rh-BMP-2. Adv Drug Deliv Rev 2003; 55: 1613-1629.
• 7 Khojasteh A, Behnia H, Naghdi N. et al. Effects of different growth factors and carriers on bone regeneration: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 116: 405-423.
• 8 Viateau V, Guillemin G, Calando Y. et al. Induction of a barrier membrane to facilitate reconstruction of massive segmental diaphyseal bone defects: an ovine model. Vet Surg 2006; 35: 445-452.
• 9 Viateau V, Guillemin G, Bousson V. et al. Long-bone critical-size defects treated with tissue-engineered grafts: a study on sheep. J Othop Res 2007; 25: 741-749.
• 10 Field JR, McGee M, Stanley R. et al. The efficacy of allogeneic mesenchymal precursor cells for the repair of an ovine tibial segmental defect. Vet Comp Orthop Traumatol 2011; 24: 113-121.
• 11 Sciadini MF, Johnson KD. Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J Orthop Res 2000; 18: 289-302.
• 12 Pluhar GE, Manley PA, Heiner JP. et al. The effect of recombinant human bone morphogenetic protein-2 on femoral reconstruction with an intercalary allograft in a dog model. J Orthop Res 2001; 19: 308-317.
• 13 Schmoekel HG, Weber FE, Hurter K. et al. Enhancement of bone healing using non-glycosylated rhBMP-2 released from a fibrin matrix in dogs and cats. J Small Anim Pract 2005; 46: 17-21.
• 14 Fellah BH, Weiss P, Gauthier O. et al. Bone repair using a new injectable self crosslinkable bone substitute. J Orthop Res 2006; 24: 628-635.
• 15 Struillou X, Rakic M, Badran Z. et al. The association of hydrogel and biphasic calcium phosphate in the treatment of dehiscence-type peri-implant defects: an experimental study in dogs. J Mater Sci Mater Med 2013; 24: 2749-2760.
• 16 Struillou X, Boutigny H, Badran Z. et al. Treatment of periodontal defects in dogs using an injectable composite hydrogel/biphasic calcium phosphate. J Mater Sci Mater Med 2011; 22: 1707-1717.
• 17 Boraiah S, Paul O, Hawkes D. et al. Complications of recombinant human BMP-2 for treating complex tibial plateau fractures: a preliminary report. Clin Orthop Relat Res 2009; 467: 3257-3262.
• 18 Garrison KR, Shemilt I, Donell S. et al. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 2010; Jun 16 (06) CD006950
• 19 Faria ML, Lu Y, Heaney K. et al. Recombinant human bone morphogenetic protein-2 in absorbable collagen sponge enhances bone healing of tibial osteotomies in dogs. Vet Surg 2007; 36: 122-131.
• 20 Schmiedt CW, Lu Y, Heaney K. et al. Comparison of two doses of recombinant human bone morphogenetic protein in absorbable collagen sponges for bone healing in dogs. Am J Vet Res 2007; 68: 834-840.
• 21 Milovancev M, Muir P, Manley PA. et al. Clinical application of recombinant human bone morphogenetic protein-2 in 4 dogs. Vet Surg 2007; 36: 132-140.
• 22 Spector DI, Keating JH, Boudrieau RJ. Immediate mandibular reconstruction of a 5 cm defect using rhBMP-2 after partial mandibulectomy in a dog. Vet Surg 2007; 36: 752-759.
• 23 Bernard F, Furneaux R, Adrega Da Silva C. et al. Treatment with rhBMP-2 of extreme radial bone atrophy secondary to fracture management in an Italian Greyhound. Vet Comp Orthop Traumatol 2008; 21: 64-68.
• 24 Arnault F, Maitre P, Cachon T. et al. Treatment of a nonunion, secondary to gunshot fracture, of the distal radius with circular external fixation and rhBMP-2 in a cat. Vet Comp Orthop Traumatol 2011; 24: 289-293.
• 25 Lewis JR, Boudrieau RJ, Reiter AM. et al. Mandibular reconstruction after gunshot trauma in a dog by use of recombinant human bone morphogenetic protein-2. J Am Vet Med Assoc 2008; 233: 1598-1604.
• 26 Crouzier T, Sailhan F, Becquart P. et al. The performance of BMP-2 loaded TCP/HAP porous ceramics with a polyelectrolyte multilayer film coating. Biomaterials 2011; 32: 7543-7554.
• 27 Kisiel M, Ventura M, Oommen OP. et al. Critical assessment of rhBMP-2 mediated bone induction: an in vitro and in vivo evaluation. J Control Release 2012; 162: 646-653.
• 28 Tuominen T, Jamsa T, Oksanen J. et al. Composite implant composed of hydroxyapatite and bone morphogenetic protein in the healing of a canine ulnar defect. Ann Chir Gynaecol 2001; 90: 32-36.
• 29 Jones CB, Sabatino CT, Badura JM. et al. Improved healing efficacy in canine ulnar segmental defects with increasing recombinant human bone morphogenetic protein-2/allograft ratios. J Orthop Trauma 2008; 22: 550-559.
• 30 Johnson KD, Frierson KE, Keller TS. et al. Porous ceramics as bone graft substitutes in long bone defects: a biomechanical, histological, and radiographic analysis. J Orthop Res 1996; 14: 351-369.
• 31 Kirker-Head CA. Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev 2000; 43: 65-92.
• 32 Kirker-Head CA, Boudrieau RJ, Kraus KH. Use of bone morphogenetic proteins for augmentation of bone regeneration. J Am Vet Med Assoc 2007; 231: 1039-1055.
• 33 Fatimi A, Tassin JF, Quillard S. et al. The rheological properties of silated hydroxypropylmethylcellulose tissue engineering matrices. Biomaterials 2008; 29: 533-543.
• 34 Laïb S, Fellah BH, Fatimi A. et al. The in vivo degradation of a ruthenium labelled polysaccharide-based hydrogel for bone tissue engineering. Biomaterials 2009; 30: 1568-1577.
• 35 Gauthier O, Bouler JM, Weiss P. et al. Kinetic study of bone ingrowth and ceramic resorption associated with the implantation of different injectable calcium-phosphate bone substitutes. J Biomed Mater Res 1999; 47: 28-35.
• 36 Itoh T, Mochizuki M, Nishimura R. et al. Repair of ulnar segmental defect by recombinant human bone morphogenetic protein-2 in dogs. J Vet Med Sci 1998; 60: 451-458.
• 37 Zara JN, Siu RK, Zhang X. et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng Part A 2011; 17: 1389-1399.
• 38 Schaefer SL, Lu Y, Seeherman H. et al. Effect of rhBMP-2 on tibial plateau fractures in a canine model. J Orthop Res 2009; 27: 466-471.
• 39 Zabka AG, Pluhar GE, Edwards III RB. et al. Histomorphometric description of allograft bone remodeling and union in a canine segmental femoral defect model: a comparison of rhBMP-2, cancellous bone graft, and absorbable collagen sponge. J Orthop Res 2001; 19: 318-327.
• 40 Mroz TE, Wang JC, Hashimoto R. et al. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 2010; 35: S86-104.
• 41 Tannoury C, An HS. Complications with use of bone morphogenetic protein-2 (BMP-2) in spine surgery. Spine J 2014; 14: 552-559.
• 42 Yokota S, Uchida T, Kokubo S. et al. Release of recombinant human bone morphogenetic protein 2 from a newly developed carrier. Int J Pharm 2003; 251: 57-66.
• 43 Kokubo S, Fujimoto R, Yokota S. et al. Bone regeneration by recombinant human bone morphogenetic protein-2 and a novel biodegradable carrier in a rabbit ulnar defect model. Biomaterials 2003; 24: 1643-1651.
• 44 McLaughlin SW, Cui Z, Starnes T. et al. Injectable thermogelling chitosan for the local delivery of bone morphogenetic protein. J Mater Sci Mater Med 2012; 23: 2141-2149.
• 45 Rabillard M, Grand JG, Dalibert E. et al. Effects of autologous platelet rich plasma gel and calcium phosphate biomaterials on bone healing in an ulnar ostectomy model in dogs. Vet Comp Orthop Traumatol 2009; 22: 460-466.
• 46 Reichert JC, Saifzadeh S, Wullschleger ME. et al. The challenge of establishing preclinical models for segmental bone defect research. Biomaterials 2009; 30: 2149-2163.